Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of Burosumab (KRN23) in Pediatric X-linked Hypophosphatemia
jRCT2080223558Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of burosumab in X-linked hypophosphataemia (XLH), rickets and osteomalacia, sponsored by Kyowa Kirin. Started Jun 2017; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)ricketsosteomalacia
Beyond the preview
Go deeper on jRCT2080223558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223558.